Machine learning analysis of RNA-Seq data to de-risk repositioning of existing FDA-approved drugs

October 30, 2018 Leave a comment 1,724 Views

AMPEL BioSolutions announced proof-of-principle for a multi-pronged approach to rank small molecules and biologics for safe, effective treatment of patients with Systemic Lupus Erythematosus (SLE) and...

RNA-Seq Blog Transcriptome Research & Industry News

Tag Archives: Stelara

Machine learning analysis of RNA-Seq data to de-risk repositioning of existing FDA-approved drugs

scDART-seq reveals distinct m6A signatures and mRNA methylation heterogeneity in single cells

A novel prognostic model based on single-cell RNA sequencing data for hepatocellular carcinoma

Dual RNA-Seq analysis of SARS-CoV-2 correlates specific human transcriptional response pathways directly to viral expression

ICRNASA 2022 – International Conference on RNA Sequencing and Analysis

New data suggest he percepta GSC RNA sequencing-based risk-stratification test can help accelerate timely treatment for patients with early-stage lung cancer

Quick determination of RNA-Seq strandedness

Benchmarking of a Bayesian single cell RNAseq differential gene expression test for dose–response study designs